Sex-based heterogeneity in response to first-line immunotherapy plus chemotherapy in advanced esophageal squamous-cell carcinoma: a meta-analysis
First-line immunotherapy plus chemotherapy can improve OS and PFS in advanced ESCC for both men and women. No evidence was found to support an association of sex with the efficacy of immunotherapy plus chemotherapy.
Authors
- Yuandong Yu
- Kai Yang (ORCID: https://orcid.org/0000-0001-7497-3911)
- Wei Shang (ORCID: https://orcid.org/0000-0001-5121-4592)
- Zhigang Zuo
- Quankai Dai
- J. He
- Jialing Liu
- Fengjun Cao
- Langhong Zeng
- Yuntian Yang
- Guoxing Wan
- Lu Wang
Institutions
- Sun Yat-sen University (CN)
- Wuhan University (CN)
- Fifth Affiliated Hospital of Sun Yat-sen University (CN)
- Renmin Hospital of Wuhan University (CN)
- Precision Research (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-27
- DOI
- https://doi.org/10.3389/fimmu.2026.1784688
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hubei University of Medicine
- Hubei University